Radiolabeling agent of antibody fragments for radionuclide therapy using At-211

Research Project

Project/Area Number	26861025
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Radiation science
Research Institution	Chiba University
Principal Investigator	Suzuki Hiroyuki 千葉大学, 薬学研究科(研究院), 助教 (00707648)
Project Period (FY)	2014-04-01 – 2016-03-31
Project Status	Completed (Fiscal Year 2015)
Budget Amount *help	¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000) Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000) Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Keywords	211At / 抗体フラグメント / 代謝性リンカー / 内用放射線治療 / 刷子縁膜酵素 / Fab / アスタチン-211
Outline of Final Research Achievements	Since the half-life of 211At (7.2 h) is relatively short, antibody fragment which showed rapid biodistribution was used. When radiolabeled antibody fragments were injected into animals, persistent localization in kidney was observed. To solve this problem, I introduced cleavable linker which is recognized by renal brush border membrane enzymes. Due to this, 211At labeled Fab reduced renal radioactivity at early post injection. The molecular design would be useful for the application to clinical radiotherapy.

Report

(3 results)